Previous 10 | Next 10 |
NEWPORT BEACH, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today announced that its strategic partner, Daewoong Pharmaceutical Co. Ltd., will invest $40 million in a five-year, unsecured, subordinated, 3% convertible note in the Company at a conversion price of $13...
Revance Therapeutics (NASDAQ: RVNC ) announces positive results from two open-label dose-escalating Phase 2a clinical trials evaluating DaxibotulinumtoxinA (DAXI) for the treatment of dynamic forehead lines following glabellar (frown) line injections and lateral canthal lines (crow...
Nova LifeStyle (NASDAQ: NVFY ) +105% . More news on: Nova LifeStyle, Inc., TDH Holdings, Inc., Rexahn Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Evolus, Inc. ( EOLS ) is a biotech company that has gained FDA approval for its lead product Jeuveau, which is the only known Neurotoxin dedicated to the aesthetics or more specific treatment of glabellar lines. Ever since the commercial launch, everyone in the aesthetics treatment industry ...
Gainers: Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +92% . More news on: Navidea Biopharmaceuticals, Inc., XpresSpa Group, Inc., Celsion Corporation, Stocks on the move, , Read more ...
Allergan ( ABBV -1.0% ) competitor Evolus ( EOLS +30.5% ), maker of Botox (onabotulinumtoxinA) rival Jeuveau (prabotulinumtoxinA-xvfs), jumps on a 10x surge in volume burning short sellers along the way. More news on: AbbVie Inc., Evolus, Inc., Revance Therapeutics, Inc....
The following slide deck was published by Evolus, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Privately held Galderma announces the results from a 120-subject study, DREAM, assessing the safety and patient satisfaction of Dysport (abobotulinumtoxinA) for the temporary treatment of moderate-to-severe glabellar lines (frown lines) between the eyebrows in adults less than 65 years old...
Image source: The Motley Fool. Evolus, Inc. (NASDAQ: EOLS) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Evolus, Inc. (EOLS) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Ashwin Agarwal – Vice President, Finance, Investor Relations and Treasury David Moatazedi – President and Chief Executive Officer Lauren Silvernail – Chief Finan...
News, Short Squeeze, Breakout and More Instantly...
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Qua...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The even...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...